Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

October 09, 2001; 57 (7) Brief Communications

Dopaminergic neurotransmission and restless legs syndrome: A genetic association analysis

A. Desautels, G. Turecki, J. Montplaisir, N. Ftouhi–Paquin, M. Michaud, V.A. Chouinard, G.A. Rouleau
First published October 9, 2001, DOI: https://doi.org/10.1212/WNL.57.7.1304
A. Desautels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Turecki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Montplaisir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Ftouhi–Paquin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Michaud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V.A. Chouinard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.A. Rouleau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Dopaminergic neurotransmission and restless legs syndrome: A genetic association analysis
A. Desautels, G. Turecki, J. Montplaisir, N. Ftouhi–Paquin, M. Michaud, V.A. Chouinard, G.A. Rouleau
Neurology Oct 2001, 57 (7) 1304-1306; DOI: 10.1212/WNL.57.7.1304

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
549

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

In order to examine the genetic substrate of the dopamine hypothesis in restless legs syndrome, we analyzed eight genes coding for receptors and enzymes related to dopaminergic transmission, using a population of 92 patients with restless legs syndrome and 182 controls matched for ethnic background. No significant differences were found in the genotypic or allelic distributions between groups. Furthermore, no effect of the loci examined was observed with stratification using clinical parameters such as age at onset or periodic leg movements during sleep index.

Restless legs syndrome (RLS) is a common disorder characterized by an irresistible desire to move the extremities associated with paresthesia. These symptoms, occurring predominantly at rest and relieved by movement, are worst at night, resulting in nocturnal insomnia and chronic sleep deprivation. Despite recurrent reports suggesting a genetic contribution to the etiology of the idiopathic form of the syndrome, few molecular genetic studies have been carried out trying to identify genes that may predispose to RLS.

Although the pathogenesis of RLS remains unknown, a growing literature suggests the involvement of the dopaminergic (DA) system in the etiology of this syndrome. The clinical improvement observed with agents increasing DA transmission (see review1) as well as evidences provided by brain imaging studies2 support the hypothesis of a central dopaminergic dysfunction in RLS.

In an attempt to test for a possible genetic role of the DA system in RLS, we performed a population-based case-control study focusing on the French Canadian population. We examined eight relevant candidate genes involved in dopaminergic transmission and metabolism: DA-receptors D1 to D5, dopamine transporter (DAT), tyrosine hydroxylase (TH), and dopamine β-hydroxylase (DBH) (table 1).

View this table:
  • View inline
  • View popup
Table 1.

Investigated candidate genes

Methods.

Subjects.

A total of 92 unrelated patients (mean age: 56.47 ± 11.69; range, 34 to 82 years) were recruited from the Sleep Disorder Center at the Hôpital du Sacré-Coeur, Montréal.

Initial diagnoses were made by two physicians with 10 years of experience in the evaluation of sleep disorders and all cases were personally reviewed by one of the co-authors (J.M.). Diagnostic criteria were based on those developed by the International RLS Study Group and included 1) leg paresthesia associated with an urge to move; 2) motor restlessness; 3) increased severity during the evening and/or at night, and 4) worsening of symptoms at rest with partial relief by movement. Exclusion criteria included presence of conditions known to be associated with RLS such as renal failure, peripheral neuropathy, anemia, and rheumatoid arthritis. None of the subjects reported the use of medication known to affect sleep, sensory, or motor functions. The presence of other sleep disorder such as sleep apnea syndrome, REM sleep behavior disorders, or narcolepsy was ruled out by interview and appropriate polysomnographic (PSG) recordings. All patients reported symptoms of RLS at least 3 nights per week for more than 6 months. PSG recordings were carried out on all patients to document sleep parameters and periodic leg movements during sleep (PLMS).

Control subjects consisted of 182 unrelated individuals. Among these, 12% were spouses documented to be free of RLS symptoms. The remainder comprised healthy controls who have not been assessed for the presence of sleep disorders. Only patients and comparison subjects of French Canadian origin were included in the current study. French Canadian ancestry was defined as having four grandparents of French Canadian origin by history. Written informed consent was obtained from all participants and the study was approved by the local ethics committee.

Nocturnal PSG recordings.

PLMS were scored according to standard criteria (i.e., increases in electromyographic [EMG] signal in anterior tibialis muscles occurring in series of at least four consecutive movements lasting 0.5 to 5 seconds with an interval between 4 and 90 seconds). The PLMS index was defined as number of periodic leg movements per hour of sleep.

Genotyping.

Genomic DNA was extracted following standard procedures. DNA was amplified and genotyped by PCR using primer sequences and conditions previously described (see table 1). All PCR and digestion products were separated on a 2% agarose gel and visualized by ethidium bromide staining under ultraviolet light. Genotype readings were carried out blind to affection status.

Statistical analysis.

Patients were categorized into three or more groups on the basis of their genotypes. Different clinical features were considered as dependent variables and we examined their distribution across alleles and genotypes. These parameters include RLS age at onset and PLMS index. The clinical characteristics of the patients regarding allelic frequencies were compared using either the Student’s t-test or the Mann–Whitney U test, whereas associations with respect to genotype frequencies were estimated using either one-way analysis of variance (ANOVA) or Kruskal–Wallis ANOVA, depending on the nature of the data. The χ2 test was performed to compare patients with controls and to compare subgroups of patients as well as to assess deviation of the genotype frequencies from Hardy–Weinberg equilibrium. Bonferroni’s corrections were carried out for multiple analyses.

Results.

Demographic and clinical data regarding the patient population are summarized in table 2. For the population studied, there was no difference between patients and controls with regard to sex ratio (χ2 = 0.957; df = 1; p = 0.328). The mean age at onset of RLS was 28.35 ± 14.31 and the mean PLMS index was 36.8 ± 31.52. Although the mean PLMS index was considered as pathologic for the whole group (i.e., >5/hour of sleep), 10% of patients presented a PLMS index within the normal range whereas 86% showed an index greater than 10. These observations concur with data published previously.

View this table:
  • View inline
  • View popup
Table 2.

Demographic, clinical, and polysomnographic characteristics for the population studied

For all the loci investigated, genotype distributions did not deviate significantly from the expected values at the Hardy–Weinberg equilibrium for either control or patient groups. As shown in table 3, for all polymorphisms studied, between-group differences in genotype frequencies were small and not significant. Similarly, no significant differences were found with regard to allele frequencies distributions when we compared proband and control groups in the overall sample (table 3).

View this table:
  • View inline
  • View popup
Table 3.

Genotype and allele frequencies for all genes studied

When investigating the alleles and genotypes distribution for age at onset of RLS and PLMS index, no significant association with any of the genes examined was found according to these clinical features. When examining exclusively patients with positive family history, individuals carrying the DA receptor D3 serine allele presented a higher PLMS index in comparison to those having the glycine allele (U test; p = 0.035). However, this difference becomes nonsignificant following Bonferroni’s correction for multiple testing.

Discussion.

This work represents the first study to examine the influence of DA candidate genes on RLS. Comparison of allele and genotype frequencies between cases and controls suggest that these loci have no major effect on vulnerability to RLS. Moreover, stratification analyses according to age at onset and PLMS index disclosed no significant differences for any of the polymorphisms examined.

These results indicate that, at least in the sample studied, DA receptors and DAT as well as TH and DBH loci are not directly involved in the etiology of RLS. From this, our findings do not provide evidence toward a genetic involvement of the dopaminergic system in RLS symptomatology. However, alternative explanations should also be considered. Indeed, it is possible that DA genes confer only a minor predisposition to RLS. If this is the case, we would have been unable to detect a positive association even though our sample had a power to detect gene effects of relatively small sizes (i.e., assuming a frequency of exposure among controls of around 20%, our study has 80% power to detect an association accounting for an OR of around 2.3).

The importance of DA in the pathogenesis of RLS cannot be ruled out as other loci implicated in the dopaminergic system have not yet been examined. Moreover, the possibility remains that other functional polymorphisms that are not in linkage disequilibrium with those investigated might affect the occurrence or the outcome of the syndrome. However, our conducting this study in a recently founded population makes this explanation unlikely. Further work is currently in progress in our laboratory to investigate other genetic factors that may confer susceptibility to RLS.

Acknowledgments

A.D. and M.M. are supported by CIHR studentships. G.A.R., G.T., and J.M. are supported by the CIHR. This research is supported in part by NIH (1R01NS37754–01A1) and by CIHR (MOP-13365).

Acknowledgment

The authors thank all the subjects who participated in this study. They also thank Sylvie Toupin, Annie Ouellet, Mireille Charron, and Daniel Filipini, MD, for their valuable work with patients’ recruitment, and Jesse Carlevaris for technical assistance.

Footnotes

  • See also pages 1153 and 1341

  • Received March 29, 2001.
  • Accepted July 14, 2001.

References

  1. ↵
    Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep . 1999; 22: 970–999.
    OpenUrlPubMed
  2. ↵
    Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology . 1999; 52: 932–937.
    OpenUrlAbstract/FREE Full Text
  3. Cichon S, Nothen MM, Erdmann J, Propping P. Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1). Hum Mol Genet . 1994; 3: 209.
    OpenUrlFREE Full Text
  4. Arinami T, Itokawa M, Enguchi H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet . 1994; 343: 703–704.
    OpenUrlCrossRefPubMed
  5. Lannfelt L, Sokoloff P, Martres MP, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Gen . 1992; 2: 249–256.
  6. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun . 1999; 258: 292–295.
    OpenUrlCrossRefPubMed
  7. Sommer SS, Sobell JL, Heston LL. A common exonic polymorphism in the human D5 dopamine receptor gene. Hum Genet . 1993; 92: 633–634.
    OpenUrlPubMed
  8. Sano A, Kondoh K, Kakimoto Y, Kondo I. A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet . 1993; 91: 405–406.
    OpenUrlCrossRefPubMed
  9. Ishiguro H, Arinami T, Saito T, et al. Systematic search for variations in the tyrosine hydroxylase gene and their associations with schizophrenia, affective disorders, and alcoholism. Am J Med Genet . 1998; 81: 388–396.
    OpenUrlCrossRefPubMed
  10. Cubells JF, van Kammen DP, Kelley ME, et al. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet . 1998; 102: 533–540.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • Genetic association studiesGenes in search of diseases
  • Association of a tumor necrosis factor α polymorphism with MS susceptibility

Topics Discussed

  • Association studies in genetics
  • Restless legs syndrome

Alert Me

  • Alert me when eletters are published
Neurology: 99 (7)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise